An observational study in Lung Cancer, sponsored by University Medical Center Groningen. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by University Medical Center Groningen · Observational
Motive:
In order to improve the treatment technique, a comprehensive follow-up program is needed to obtain all relevant patient, treatment and toxicity data from lung cancer patients.
Goal:
To set-up and maintain a database containing treatment results in terms of tumor control, side effects, complications and patient-reported quality of life.
A standard database of patients receiving photon treatment will be created. These data are then linked to dose-volume data of radiotherapy, with the aim to build prediction models for both tumor control and toxicity after radio (chemo) therapy that can later be used for selecting patients for proton treatment.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's planned enrollment of 10,000 is above the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →University Medical Center Groningen is the lead sponsor of 609 studies on the registry; 174 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with Non-Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer - Limited Disease (SCLC-LD) or thymoma or lungmetastases (treated with stereotactic radiotherapy), receiving radiotherapy dose > 40 Gy.
Exclusion Criteria:
Also known as: Chemoradiation
Acute toxicity
esophagitis (Common Terminology Criteria for Adverse Events, version 4.0)
Time frame: Highest during and within 2 weeks after last day of radiation therapy
Late toxicity
esophagitis (Common Terminology Criteria for Adverse Events, version 4.0); pneumonitis (Common Terminology Criteria for Adverse Events, version 4.0)
Time frame: Highest within one year after last day of radiation therapy
Overall survival
Time frame: at 1 year after first day of radiation therapy
Overall survival
Time frame: at 2 years after first day of radiation therapy
Overall survival
Time frame: at 3 years after first day of radiation therapy
Overall survival
Time frame: at 4 years after first day of radiation therapy
Overall survival
Time frame: at 5 years after first day of radiation therapy
Loco-regional tumor control
Time frame: at 1 year after first day of radiation therapy
Loco-regional tumor control
Time frame: at 2 years after first day of radiation therapy
Loco-regional tumor control
Time frame: at 3 years after first day of radiation therapy
Patient-rated symptoms and Quality-of-Life
Time frame: Within 1 week before or after last day of radiation therapy
Patient-rated symptoms and Quality-of-Life
Time frame: at 3 months after first day of radiation therapy
Patient-rated symptoms and Quality-of-Life
Time frame: at 6 months after first day of radiation therapy
Patient-rated symptoms and Quality-of-Life
Time frame: at one year after first day of radiation therapy
Patient-rated symptoms and Quality-of-Life
Time frame: at 2 years after first day of radiation therapy
Patient-rated symptoms and Quality-of-Life
Time frame: at 3 years after first day of radiation therapy
Patient-rated symptoms and Quality-of-Life
Time frame: at 4 years after first day of radiation therapy
Patient-rated symptoms and Quality-of-Life
Time frame: at 5 years after first day of radiation therapy
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Medical Center Groningen